Pharma Business - October 1, 2019
Lobsor receives approval for Lecigon in Denmark, Finland and Norway
Lobsor Pharmaceuticals has announced that Lecigon has been approved, and that the Swedish Medical Products Agency (MPA) has confirmed End of Procedure according to the European Mutual Recognition Procedure (MRP) including Denmark, Finland and Norway. “We are delighted to have now received confirmation of End of Procedure, particularly since it came two months earlier than […]
Pharma Business - April 9, 2019
Lobsor’s Lecigon included on Sweden’s list of reimbursed drugs
Lobsor Pharmaceuticals has reported that following Swedish MPA market approval in October 2018, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Lecigon on Sweden’s list of reimbursed drugs. A major milestone “This marks a major milestone as Sweden becomes the first country to offer patients this new therapeutic system for symptomatic treatment of […]
Intellectual Property - March 20, 2019
Lobsor granted US patent
Lobsor Pharmaceuticals has been granted the US patent covering a pharmaceutical composition for the treatment of neurodegenerative disorders such as Parkinson’s disease. Lobsor has earlier received market authorization by the Swedish Medical Products Agency (MPA) for their lead product, Lecigon, a new therapeutic system for symptomatic treatment of Advanced Parkinson’s disease (APD). Lecigon comprises the […]
